𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Comorbidities and polypharmacy impact on complete cytogenetic response in chronic myeloid leukaemia elderly patients

✍ Scribed by Iurlo, Alessandra; Ubertis, Anna; Artuso, Silvia; Bucelli, Cristina; Radice, Tommaso; Zappa, Manuela; Cattaneo, Daniele; Mari, Daniela; Cortelezzi, Agostino

Book ID
122116849
Publisher
Elsevier Science
Year
2014
Tongue
English
Weight
153 KB
Volume
25
Category
Article
ISSN
0953-6205

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Cytogenetic and molecular responses in c
Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose
✍ Massimo Breccia; Laura Cannella; Caterina Stefanizzi; Roberto Latagliata; Mauro πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 76 KB

## Abstract Imatinib mesylate is the gold standard treatment of chronic myeloid leukaemia (CML) and 400 mg/day is considered the standard dose. Although it is generally well tolerated, some patients require temporary drug discontinuation and permanent dose reduction because of haematological or non

Efficacy and safety of imatinib in patie
Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-Ξ±
✍ Susan Branford; Timothy Hughes; Alvin Milner; Rachel Koelmeyer; Anthony Schwarer πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 201 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. Interferon‐alpha (IFN‐α) confers a survival advantage for the minority of patients with chronic myeloid leukemia (CML) who achieve a complete cytogenetic response. The question of whether IFN‐α‐responsive patients can experience further improvements with imatinib has not